drugset / Trial / NCT06722183
Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
Phase 2
Recruiting
33 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler · collab
NaSingle-groupOpen-labelTreatment
Summary
The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Futibatinib | Small molecule | 20 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |